Appendixes
Appendix A.—Health Program Advisory Committee and Acknowledgments

HEALTH PROGRAM ADVISORY COMMITTEE

Sidney S. Lee, Chair
Michael Reese Hospital and Medical Center

Stuart H. Altman*
Florence Heller School
Brandeis University

Carroll L. Estes
Department of Social and Behavioral Sciences
School of Nursing
University of California, San Francisco

Rashi Fein
Department of Social Medicine and Health Policy
Harvard Medical School

Melvin A. Glasser
Health Security Action Council-
Committee for National Health Insurance

Patricia King
Georgetown Law Center

Joyce C. Lashof
School of Public Health
University of California, Berkeley

Margaret Mahoney
The Commonwealth Fund

Frederick Mosteller
Department of Health Policy and Management
School of Public Health
Harvard University

Mitchell Rabkin*
Beth Israel Hospital
Boston, Mass.

Dorothy P. Rice
Department of Social and Behavioral Sciences
School of Nursing
University of California, San Francisco

Richard K. Riegelman
George Washington University
School of Medicine

Walter L. Robb
Medical Systems Operations
General Electric
Milwaukee, Wis.

Frederick C. Robbins
Institute of Medicine

Rosemary Stevens
Department of History and Sociology Science
University of Pennsylvania

● Until April 1983.
ACKNOWLEDGMENTS

The development of this case study was greatly aided by the advice and review of a number of people in addition to the Advisory Panel for the assessment of Medical Technology and Costs of the Medicare care Program and the Health Program Advisory Panel. The case study director and OTA staff would like to express their appreciation especially to the following individuals:

Cheryl Anderson, Advocacy International, Ltd.
Jack M. Anthony, Travenol Laboratories, Inc.
Thomas Asher, Immunogenetics, Inc.
Robert Berenson, Washington, D.C.
Eugene Berkman, Tufts New England Medical Center
Gary F. Brown, Seattle, Wash.
Meredith F. Buco, Blue Cross/Blue Shield Association
Maria Charest, Arthur D. Little, Inc., Cambridge, Mass.
Arthur A. Ciarkowski, Food and Drug Administration
Vincent Ciuryla, E. I. du Pent de Nemours & Co., Inc.
P. P. Clymer, Office of Technology Assessment
Robert M. Collins, Cobe Laboratories, Inc.
Dennis Cotter, Office of Health Technology Assessment
W. Palmer Dearing, Blue Cross/Blue Shield Association
Vincent T. DeVita, Jr., National Cancer Institute
Allen J. Douma, American Medical Association
Frances Edmondson, Travenol Laboratories, Inc.
Lenny Friedman, American Red Cross
W. Bradford Gary, Travenol Laboratories, Inc.
Murray Goldstein, National Institute of Neurological and Communicative Disorders and Stroke
Max I. Hamburger, State University of New York at Stony Brook

Steven Heyse, National Institute of Arthritis, Diabetes, and Digestive and Kidney Disease
Terry Hollis, Blue Cross/Blue Shield of Massachusetts
Douglas W. Huestis, University of Arizona
John Verrier Jones, Dalhousie University, Nova Scotia, Canada
Richard Landfield, Goodell, Landfield, Becker, Green & Martingale, Washington, D.C.
Claude Lenfant, National Heart, Lung, and Blood Institute
Joshua Levy, Immunogenetics, Inc.
L. M. Magner, E. I. du Pent de Nemours & Co., Inc.
Guy M. McKhann, Johns Hopkins Hospital
Donald Myers, RMR Health and Hospital Consultants, Inc.
Terri Louise Nally, American Chemical Society
Nan Newell, Office of Technology Assessment
Robert K. Oldham, National Cancer Institute
Robert W. Reilly, American Blood Resources Association
J. Gerald Sandier, American Red Cross
Ira D. Singer, Project Hope
Glenda Sweeney, American Red Cross
Garry Vibert, Parker-Hannifin Corp.
Donald Young, Health Care Financing Administration